PIK3CA and acute myeloid leukemia: Additionally, PI3K suppression potentially reinforced the antileukemic property of a commonly used chemotherapeutic drug in AML treatment, idarubicin, highlighting the promising effect of the inhibitor either as a single agent or in combined-modality treatment.